Emerging drugs for endometriosis

Bibliography

• JANNE O, KAUPPILA A, KOKKO E, LANTTO T, RONNBERG L, VINKO R: Estrogen and progestin receptors in endometriosis lesions: comparison with endometrial tissue. Am. J. Obstet. Gynecol. (1981) 141:562–566.
   PubMed Web of Science ®Google Scholar
• METZGER DA, OLIVE DL: Limited hormonal responsiveness of ectopic endometrium. Hum. Pathol. (1988) 19:1417–1424.
   PubMed Web of Science ®Google Scholar
• NISOLLE M, CASANAS-ROUX E, ANAF V, MINE JM, DONNEZ J: Morphometric study of the stromal vascularization in peritoneal endometriosis. Feral. Stern. (1993) 59:681–684.
   PubMed Web of Science ®Google Scholar
• BROSENS IA: Endometriosis-a disease because it is characterized by bleeding. Am. J. Obstet. Gynecol. (1997) 176:263–267.
   PubMed Web of Science ®Google Scholar
• BOLING RO, ABBASI R, ACKERMAN G, SCHIPUL AH Jr, CHANEY SA: Disability from endometriosis in the United States Army. Reprod. Med. (1988) 33(1):49–52.
   PubMed Web of Science ®Google Scholar
• WILCOX LS, KOONIN LM, POKRAS R, STRAUSS LT, XIA Z, PETERSON HB: Hysterectomy in the United States 1988-1990. Obstet. Gynecol. (1994) 83:549–555.
   PubMed Web of Science ®Google Scholar
• MAHMOOD TA, TEMPLETON A: Prevalence and genesis of endometriosis. Hum. Reprod. (1991) 6(4):544–549.
   PubMed Web of Science ®Google Scholar
• HASSON HM: Incidence of endometriosis in diagnostic laparoscopy. I Reprod. Med. (1976) 16(3):135–138.
   PubMed Web of Science ®Google Scholar
• SANGI-HAGHPEYKAR H, POINDEXTER AN 3rd: Epidemiology of endometriosis among parous women. Obstet. Gynecol. (1995) 85(6):983–992.
   PubMed Web of Science ®Google Scholar
• CRAMER DW, MISSMER SA: The epidemiology of endometriosis. Ann. NY Acad. Sci. (2002) 955:11-22 (Discussion 34–6, 396–406).
   Google Scholar
• DUIGNAN NM, JORDAN JA, COUGHLAN BM, LOGAN-EDWARDS R: One thousand consecutive cases of diagnostic laparoscopy. Obstet. Gynaecol. BE Commonw (1972) 79(10:1016–1024.
   PubMedGoogle Scholar
• CRAMER DW, WILSON E, STILLMAN RJ et al.: The relation of endometriosis to menstrual characteristics, smoking, and exercise. JAMA (1986) 255(14):1904–1908.
   PubMed Web of Science ®Google Scholar
• WILLIAMS TJ, PRATT JH: Endometriosis in 1,000 consecutive celiotomies: incidence and management. Am. J. Obstet. Gynecol. (1977) 129(3):245–250.
   PubMed Web of Science ®Google Scholar
• KRESCH AJ, SEIFER DB, SACHS LB, BARRESE I: Laparoscopy in 100 women with chronic pelvic pain. Obstet. Gynecol. (1984) 64(5):672–674.
   PubMed Web of Science ®Google Scholar
• BROSENS IA, VERLEYEN A, CORNILLIE F: The morphologic effect of short-term medical therapy of endometriosis. Am. Obstet. Gynecol. (1987) 157:1215–1221.
   PubMed Web of Science ®Google Scholar
• NISOLLE-POCHET M, CASANAS-ROUX F, DONNEZ J: Histologic study of ovarian endometriosis after hormonal therapy. Feral. Stern. (1988) 49:432–436.
   PubMed Web of Science ®Google Scholar
• CANDIANI GB, VERCELLINI P, FEDELE L, BOCCIOLONE L, BIANCHI C: Medical treatment of mild endometriosis and infertility: analysis of a failure. Hum. Reprod. (1990) 5:901–905.
   PubMed Web of Science ®Google Scholar
• ADAMSON GD, NELSON HP: Surgical treatment of endometriosis. Obstet. Gynecol. Clin. North. Am. (1997) 24:375–409.
   PubMed Web of Science ®Google Scholar
• GREENBLATT RB, DMOWSKI WP, MAHESH VB, SCHOLER HF: Clinical studies with an antigonadotropin-Danazol. Fertil Steril. (1971) 22(2):102–112.
   PubMed Web of Science ®Google Scholar
• •The first clinical study on danazol for the treatment of endometriosis.
   Google Scholar
• MARCHINI M, FEDELE L, BIANCHI S,DI NOLA G, NAVA S, VERCELLINI P: Endometrial patterns during therapy with danazol or gestrinone for endometriosis. Hum. Pathol. (1992) 23:51–56.
   PubMed Web of Science ®Google Scholar
• ADAMSON GD, PASTA DJ: Surgical treatment of endometriosis-associated infertility: meta-analysis compared with survival analysis. Am. J. Obstet. Gynecol. (1994) 171:1488–1496.
   PubMed Web of Science ®Google Scholar
• IGARASHI M, IIZUKA M, ABE Y, IBUKI Y: Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis. Hum. Reprod. (1998) 13:1952–1956.
   PubMed Web of Science ®Google Scholar
• FEDELE L, BIANCHI S, VIEZZOLI T, ARCAINI L, CANDIANI GB: Gestrinone versus danazol in the treatment of endometriosis. Feral. Steril. (1989) 51:781–785.
   PubMed Web of Science ®Google Scholar
• DAWOOD MY, OBASIOLU CW, RAMOS J, KHAN-DAWOOD FS: Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am. .1 Obstet. Gynecol. (1997) 176:387–394.
   Google Scholar
• OSTEEN KG, BRUNER-TRAN KL, ONG D, EISENBERG E: Paracrine mediators of endometrial matrix metalloproteinase expression: potential targets for progestin-based treatment of endometriosis. Ann. NY Acad. Sci. (2002) 955:139–146.
   PubMed Web of Science ®Google Scholar
• HANEY AF, WEINBERG JB: Reduction ofthe intraperitoneal inflammation associated with endometriosis by treatment with medroxyprogesterone acetate. Am. Obstet. Gynecol (1988) 159(2):450–454.
   PubMed Web of Science ®Google Scholar
• VERCELLINI P, DE GIORGI O, OLDANI S, CORTESI I, PANAZZA S, CROSIGNANI PG: Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am. J. Obstet. Gynecol. (1996) 175(2):396–401.
   PubMed Web of Science ®Google Scholar
• VERCELLINI P, FEDELE L, PIETROPAOLO G, FRONTINO G, SOMIGLIANA E, CROSIGNANI PG: Progestogens for endometriosis: forward to the past. Hum. Reprod. Update. (2003) 9(4):387–396.
   PubMed Web of Science ®Google Scholar
• •Review of clinical studies of progestogens for endometriosis.
   Google Scholar
• HARRISON RF, BARRY-KINSELLA C: Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Feral Steril. (2000) 74(1)24–30.
   PubMed Web of Science ®Google Scholar
• BERGQVIST A, THEORELL T: Changes in quality of life after hormonal treatment of endometriosis. Acta Obstet. Gynecol Scand. (2001) 80(7):628–637.
   PubMed Web of Science ®Google Scholar
• MORAN C, ALCIVIA JC, GARCIA-HERNANDEZ E, CASTRO J: Treatment of endometriosis with cyproterone acetate. Preliminary report. Arch. Med. Res. (1996) 27(4):535–538.
   PubMed Web of Science ®Google Scholar
• VERCELLINI P, DE GIORGI O, MOSCONI P, STELLATO G, VICENTINI S, CROSIGNANI PG: Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Feral. Steril. (2002) 77(1):52–61.
   PubMed Web of Science ®Google Scholar
• MUNEYYIRCI-DELALE O, KARACAN M: Effect of norethindrone acetate in the treatment of symptomatic endometriosis. mt. I Feral. Womens Med. (1998) 43(1):24–27.
   PubMed Web of Science ®Google Scholar
• MOORE C, KOHLER G, MULLER A: The treatment of endometriosis with dienogest. Drugs Today (1999) 35:41–52.
   Web of Science ®Google Scholar
• OVERTON CE, LINDSAY PC, JOHAL B et al.: A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Feral. Steril. (1994) 62(4):701–707.
   PubMed Web of Science ®Google Scholar
• REGIDOR PA, REGIDOR M, SCHMIDT M et al.: Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecol Endocrinol. (2001) 15(3):202–209.
   PubMed Web of Science ®Google Scholar
• FEDELE L, BIANCHI S, RAFFAELLI R, ZANCONATO G: Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. Maturitas (1999) 32(3):189–193.
   PubMed Web of Science ®Google Scholar
• YLANEN K, LAATIKAINEN T, LAHTEENMAKI P, MOO-YOUNG AJ: Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses. Acta Obstet. Gynecol Scand. (2003) 82(2):167–172.
   PubMed Web of Science ®Google Scholar
• VERCELLINI P, CORTESI I, CROSIGNANI PG: Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fe/tn. Steril. (1997) 68:393–401.
   PubMed Web of Science ®Google Scholar
• DLUGI AM, MILLER JD, KNITTEL J: Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Feral Steril. (1990) 54:419–427.
   PubMed Web of Science ®Google Scholar
• SHAW RW: GnRH analogues in the treatment of endometriosis - rationale and efficacy. In: Modern Approaches to Endometriosis. Thomas E, Rock J (Eds), Kluwer Academic Publishers, London (1990):257–274.
   Google Scholar
• HORNSTEIN MD, YUZPE AA, BURRY KA, HEINRICHS LR, BUTTRAM VL Jr, ORWOLL ES: Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil. Steril (1995) 63:955–962.
   PubMed Web of Science ®Google Scholar
• FEDELE L, BIANCHI S, BOCCIOLONE L, DI NOLA G, FRANCHI D: Buserelin acetate in the treatment of paelvic pain associated with minimal and mild endometriosis: a controlled study. Fe/tn. Steril. (1993) 59:516–521.
   PubMed Web of Science ®Google Scholar
• PARAZZINI F: Medical treatment for pelvic pain in endometriosis: an overeview of studies on danazol, medroxyprogesterone acetate, gestrinone and gonadotropin releasing hormone agonists. In: Endometriosis and pelvic path: Time of review. Crosignani PG, Vercellini P (Eds) (1994):61–81.
   Google Scholar
• MILLER JD, SHAW RW, CASPER RF et al.: Historical prospective cohort study of the recurrence of pain after discontinuation of treatment with danazol or a gonadotropin-releasing hormone agonist. Fertil. Steril (1998) 70:293–296.
   PubMed Web of Science ®Google Scholar
• FEDELE L, BIANCHI S, ARCAINI L, VERCELLINI P, CANDIANI GB: Buserelin versus danazol in the treatment of endometriosis-associated infertility. Am. Obstet. Gynecol. (1989) 161:871–876.
   PubMed Web of Science ®Google Scholar
• HENZL MR, CORSON SL, MOGHISSI K, BUTTRAM VC, BERQVIST C, JACOBSON J: Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl. J. Med. (1988) 318:485–489.
   PubMed Web of Science ®Google Scholar
• SHAW RW: Zoladex Endometriosis Study Team. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Fertil. Steril (1992) 58:265–272.
   PubMed Web of Science ®Google Scholar
• MATTA WH, SHAW RW, HESP R, EVANS R: Reversible trabecular bone density loss following induced hypoestrogenism with GnRH analogue buserelin in premenopausal women. Clin. Endocrinol (1988) 29:45–51.
   PubMed Web of Science ®Google Scholar
• SURREY ES: Add-back therapy: extending safety and efficacy of GnRH analogues in the gynecologic patient. Gynecol. Obstet. Invest. (1998) 45\(Suppl. 1):31–34.
   PubMed Web of Science ®Google Scholar
• BARBIERI RL: Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment. I Reprod. Med. (1998) 43\(Suppl. 3):287–292.
   PubMed Web of Science ®Google Scholar
• CEDARS M, LU K, MELDRUM DR, JUDD HL: Treatment of endometriosis with a long-acting gonadotropin releasing hormone agonist plus medroxyprogesterone acetate. Obstet. Gynecol. (1990) 75:641–645.
   PubMed Web of Science ®Google Scholar
• SURREY ES, GAMBONE JC, LU JKH, JUDD HL: The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Feral Stern. (1990) 53:620–626.
   PubMed Web of Science ®Google Scholar
• SURREY ES, VOIGT B, FOURNET N, JUDD HL: Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone 'add-back' therapy. Feral. Stern. (1995) 63:747–755.
   PubMed Web of Science ®Google Scholar
• KIILHOLMA P, TUIMALA R, KIVINEN S, KORHONEN M, HAGMAN E: Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Feral Steril. (1995) 64:903–908.
   PubMed Web of Science ®Google Scholar
• HOWELL R, EDMONDS D, DOWSETT M, CROOK D, LEES B, STEVENSON J: Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: A randomized clinical trial. Feral. Steril. (1995) 64:474–481.
   PubMed Web of Science ®Google Scholar
• MOGHISSI KS, SCHLAFF WD, OLIVE DL, SKINNER MA, YIN H: Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil. Steril (1998) 69:1056–1062.
   PubMed Web of Science ®Google Scholar
• HORNSTEIN MD, SURREY ES, WEISBERG GW, CASINO L: The Lupron Add-Back Study Group. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet. Gynecol. (1998) 91:16–24.
   PubMed Web of Science ®Google Scholar
• ••Establishes the state of the art in GnRHanalogues and add-back therapy.
   Google Scholar
• PARAZZINI F, DI CINTIO E, CHATENOUD L et al: Estroprogestin versus gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. Gruppo Italian° per lo Studio dell'Endometriosi. Eur. I Obstet. Gynecol. Reprod. Biol. (2000) 88(1):11–14.
   PubMed Web of Science ®Google Scholar
• •Shows the efficacy of OC for endometriosis-related pain.
   Google Scholar
• VERCELLINI P, TRESPIDI L, COLOMBO A, VEND OLA N, MARCHINI M, CROSIGNANI PG: A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil. Stern. (1993) 60(1):75–79.
   PubMed Web of Science ®Google Scholar
• VERCELLINI P, FRONTINO G, DE GIORGI O, PIETROPAOLO G, PASIN R, CROSIGNANI PG: Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhoea that does not respond to a cyclic pill regimen. Feral. Steril. (2003) 80(3):560–563.
   PubMed Web of Science ®Google Scholar
• ZEITOUN KM, BULUN SE: Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil. Stern. (1999) 72(6):961–969.
   PubMed Web of Science ®Google Scholar
• •The first clinical srudy on aromatase inhibitors for the treatment of endometriosis.
   Google Scholar
• SANTEN RJ, HARVEY HA: Use of aromatase inhibitors in breast carcinoma. Endocr. Relat. Cancer (1999) 6(1):75–92.
   PubMed Web of Science ®Google Scholar
• KUDOH M, SUSAKI Y, IDEYAMA Y, NANYA T, MORI M, SHIKAMA H: Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis. J. Steroid Biochem. Mol. Biol. (1997) 63(1-3):75–80.
   PubMed Web of Science ®Google Scholar
• YANO S, IKEGAMI Y, NAKAO K: Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Arzneimittelforschung (1996) 46(2):192–195.
   PubMed Web of Science ®Google Scholar
• BUZDAR AU: Role of aromatase inhibitors in advanced breast cancer. Endocr. Relat. Cancer (1999) 6(2):219–225.
   PubMed Web of Science ®Google Scholar
• MIT WALLY MF, CASPER RF: Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Feral. Stern. (2001) 75(2):305–309.
   PubMed Web of Science ®Google Scholar
• AILAWADI RK, JOBANPUTRA S, KATARIA M, GURATES B, BULUN SE: Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Feral. Steril. (2004) 81(2):290–296.
   PubMed Web of Science ®Google Scholar
• SOYSAL S, SOYSAL ME, OZER S, GUL N, GEZGIN T: The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum. Reprod. (2004) 19(1):160–167.
   PubMed Web of Science ®Google Scholar
• FEDELE L, BIANCHI S, RAFFAELLI R, PORTUESE A, DORTA M: Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Feral. Steril. (1997) 68(3):426–429.
   PubMed Web of Science ®Google Scholar
• VERCELLINI P, AIMI G, PANAZZA S, DE GIORGI O, PESOLE A, CROSIGNANI PG: A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhoea associated with endometriosis: a pilot study. Fe/tn. Steril. (1999) 72(3):505–508.
   PubMed Web of Science ®Google Scholar
• FEDELE L, BIANCHI S, ZANCONATO G, PORTUESE A, RAFFAELLI R: Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Feral. Steril. (2001) 75(3):485–488.
   PubMed Web of Science ®Google Scholar
• LOCKHAT FB, EMEMBOLU JO, KONJE JC: The evaluation of the effectiveness of an intrauterine-administered progestogen ffevonorgestreff in the symptomatic treatment of endometriosis and in the staging of the disease. Hum. Reprod. (2004) 19(1):179–184.
   PubMed Web of Science ®Google Scholar
• •Shows that medicated IUD is effective for pelvic endometriosis (in addition to adenomyosis and rectovaginal endometriosis).
   Google Scholar
• KETTEL LM, HUMMEL WP: Modern medical management of endometriosis. Obstet. Gynecol. Cliii. North Am. (1997) 24:361–373.
   PubMed Web of Science ®Google Scholar
• KETTEL LM, MURPHY AA, MORTOLA JF, LIU JH, ULMANN A, YEN SSC: Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Feral. Steril (1991) 56:402–407.
   PubMed Web of Science ®Google Scholar
• KETTEL LM, MURPHY AA, MORALES AJ, ULMANN A, BAULIEU EE, YEN SSC: Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Feral. Steril. (1996) 65:23–28.
   PubMed Web of Science ®Google Scholar
• KETTEL LM, MURPHY AA, MORALES AJ, YEN SS: Preliminary report on the treatment of endometriosis with low-
   Google Scholar
• •• dose mifepristone (RU 486). Am. Obstet. Cynecol (1998) 178:1151–1156.
   PubMed Web of Science ®Google Scholar
• HUIRNE JA, LAMBALK CB: Gonadotropin-releasing-hormone-receptor antagonists. Lancet (2001) 358(9295):1793–1803.
   PubMed Web of Science ®Google Scholar
• MARTHA PM, GRAY ME, CAMPION M, KUCA B, GARNICK MB, ABARELIX-DEPOT A: Potent pure GnRH antagonist, rapidly induced sustained suppression of the pituitary-gonadal axis in women with endometriosis. Feral Sten?. (1999) 71\(Suppl. 1):S9.
   Web of Science ®Google Scholar
• HALME J, BECKER S, HASKILL S: Altered maturation and function of peritoneal macrophages: possible role in the pathogenesis of endometriosis. Am. J. Obstet. Cynecol. (1987) 156:783–789.
   PubMed Web of Science ®Google Scholar
• ZREIK TG, OLIVE DL: Pathophysiology - the biologic principles of disease. Obstet. Cynecol. Clin. North Am. (1997) 24:259–268.
   PubMed Web of Science ®Google Scholar
• ••Explains the rationale for pathophysiology- based therapy of endometriosis.
   Google Scholar
• SHARPE-TIMMS KL: Basic research in endometriosis. Obstet. Cynecol. Clin. North. Am. (1997) 24:269–290.
   PubMed Web of Science ®Google Scholar
• MANDELL GL: Cytokines, phagocytes, and pentoxifylline. Cardiovasc. Pharmacol (1995) 25\(Suppl. 2):S20–S22.
   PubMed Web of Science ®Google Scholar
• BALASCH J, CREUS M, FABREGUES F: Pentoxitylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum. Reprod. (1997) 12(9):2046–2050.
   PubMed Web of Science ®Google Scholar
• NOTHNICK WB: Treating endometriosis as an autoimmune disease. Feral Stern. (2001) 76(2):223–231.
   PubMed Web of Science ®Google Scholar
• RAZA A: Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. (2000) 50(3):229–235.
   PubMed Web of Science ®Google Scholar
• D'ANTONIO M, MARTELLI F, PEANO S, PAPOIAN R, BORRELLI F: Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J. Reprod. Immunol.n (2000) 48(2):81–98.
   Web of Science ®Google Scholar
• D'HOOGE TM, CUNEO S, NUGENT N, CHAI D,DEER F, MWENDA J: Recombinant human TNF binding protein-1 (r-h TBP-1) inhibits the development of endometriosis in baboons: a prospective, randomised, placebo- and drug-controlled study. Feral. Steril (2001) 76:Sl.
   Google Scholar
• BRAUN DP, DMOWSKI WP: Endometriosis: abnormal endometrium and dysfunctional immune response. Curl: Opin. Obstet. Cynecol. (1998) 10(5):365–369.
   PubMed Web of Science ®Google Scholar
• SOMIGLIANA E, VIGANO P, VIGNALI M: Endometriosis and unexplained recurrent spontaneous abortion: pathological states resulting from aberrant modulation of natural killer cell function? Hum. Reprod. Update (1999) 5(1):40–51.
   PubMed Web of Science ®Google Scholar
• INGELMO JM, QUEREDA F, ACIEN P: Intraperitoneal and subcutaneous treatment of experimental endometriosis with recombinant human interferon-alpha-2b in a murine model. Feral. Steril (1999) 71(5):907–911.
   PubMed Web of Science ®Google Scholar
• SOMIGLIANA E, VIGANO P, ROSSI G, CARINELLI S, VIGNALI M, PANINA-BORDIGNON P: Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis. Hum. Reprod. (1999) 14(12):2944–2950.
   PubMed Web of Science ®Google Scholar
• ALT FM, FATEEN B, EZZET A, BADAWY H, RAMADAN A, EL-TOBGE A: Laparoscopic intraperitoneal injection of human interferon-a2, in the treatment of pelvic endometriosis: a new modality. Obstet. Cynecol. (2000) 95(Suppl.):478–479.
   Google Scholar
• NISOLLE M, DONNEZ J: Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Feral. Steril (1997) 68(4):585–596.
   PubMed Web of Science ®Google Scholar
• KITAWAKI J, NOGUCHI T, AMATSU T et al: Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium. Biol. Reprod. (1997) 57(3):514–519.
   PubMed Web of Science ®Google Scholar
• SIMPSON JL, BISCHOFF FZ, KAMAT A, BUSTER JE, CARSON SA: Genetics of endometriosis. Obstet. Cynecol. Clin. North Am. (2003) 30(1):21–40, vii.
   PubMedGoogle Scholar
• ESKENAZI B, MOCARELLI P, WARNER M et al: Serum dioxin concentrations and endometriosis: a cohort study in Seveso, Italy. Environ. Health Perspect. (2002) 110(7):629–634.
   PubMed Web of Science ®Google Scholar